Compare Lennar Corporation (LEN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs TG Therapeutics Inc — how do they compare? Lennar Corporation trades at $87.48 (market cap $21.05B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Lennar Corporation is far larger — about 2.8× TG Therapeutics Inc's market cap, and Lennar Corporation pays a 2.28% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LEN | TGTX | |
|---|---|---|
Market Cap | $21.05B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.40 | $59.06 |
52-Week Low | $81.84 | $26.94 |
Enterprise Value | $24.93B | $7.84B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $85.70, up 0.12% today, with a neutral technical signal and bullish moving averages. The stock shows mixed earnings performance, missing EPS estimates in three of the last four quarters, while maintaining a modest dividend. Valuation ratios appear reasonable with a P/E of 13.72 and P/B below 1. Recent news highlights price volatility and analyst scrutiny amid housing market pressures.
LEN presents a cautious opportunity with undervalued metrics but faces headwinds from declining profitability and housing affordability challenges. Analyst consensus leans buy (46%) with a $84.30 target, near current price. Key risks include earnings misses, rising mortgage rates, and competitive threats from disruptors like Boxabl. Upside depends on execution improvement and market stabilization.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
